Scientific recommendation on classification of advanced therapy medicinal products

Disclaimer: This document is a summary for public release of a scientific recommendation on classification of advanced therapy medicinal products. The original text adopted by the Committee for Advanced Therapies (CAT) has been redacted to delete commercially confidential information.

The present scientific recommendation refers exclusively to the case as presented to the European Medicines Agency (EMA) without prejudice to future evaluations by the Agency.

It is stressed that the scientific recommendation on advanced therapy classification does not amount to any endorsement of the plausibility of the product, including the mode of action or therapeutic indication(s) claimed by the applicant.

Brief description (or name when available) of the active substance(s)

Autologous skeletal muscle derived cells attached to poly(DL-lactide-co-glycolide) microparticles.

Brief description of the finished product

Suspension for injection.

Proposed indication

Treatment of faecal incontinence and anorectal malformation.

EMA/CAT conclusion

The procedure was finalised on 28 March 2019 for the following recommendation.

On the basis that the product:
• contains cells that have been subject to substantial manipulation;
• incorporates, as an integral part of the product, a medical device,

the EMA/CAT considers that the product falls within the definition of a tissue engineered product and combined advanced therapy medicinal product, as provided in Article 2(1) of Regulation (EC) 1394/2007.